Explore ›
Finding
Finding
null
The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, with 5-year OS rates of 60% for both regimens and 5-year CRD rates of 53% vs 55%.
| Effect size | 5-year OS 60% vs 60% |
| Follow-up | 5 years |
| Comparator | Hyper-CVAD adult chemotherapy regimen (n=102, median age 27 years, historical comparison at same institution) |
| Effect summary | null; 5-year OS 60% vs 60% |
| Effect modifiers | [{"modifier": "Age (21 or younger vs older than 21)", "interaction_p": "", "direction": "null", "stratum_details": "Age <=21: 5-year OS 65% ABFM vs 68% HCVAD; Age >21: 57% ABFM vs 58% HCVAD", "plain_language": "Age did not change whether ABFM or hyper-CVAD was better \u2014 outcomes were similar in both younger and older AYA patients", "annotation_notes": "Subgroup analysis presented in Figure 1C and 1D"}, {"modifier": "CD20 expression (less than 20% vs 20% or more)", "interaction_p": "", "direction": "null", "stratum_details": "CD20 <20%: 5-year OS 69% ABFM vs 61% HCVAD; CD20 >=20%: 46% ABFM vs 61% HCVAD (differences not statistically significant)", "plain_language": "CD20 expression level did not significantly change the comparison between the two regimens, though there was a numerical trend favoring hyper-CVAD in CD20-positive patients", "annotation_notes": "Differences were not statistically significant per paper text"}] |
Connected entities
Conditions
Outcomes
Populations
Source
PMC5558853
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen